Tags

Type your tag names separated by a space and hit enter

Urinary nerve growth factor can predict therapeutic efficacy in children with monosymptomatic nocturnal enuresis.
Neurourol Urodyn. 2019 11; 38(8):2311-2317.NU

Abstract

AIM

To determine the urinary levels of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in children with monosymptomatic nocturnal enuresis (MNE) and evaluate whether these factors can be used as biomarkers for the treatment outcome.

METHODS

NGF and BDNF levels were measured and compared in 38 children (28 boys and 10 girls) with MNE and 25 children (18 boys and 7 girls) with no urinary symptoms were assessed. The mean ages in the patient and control groups were 9 and 10 years, respectively (P = .49). The patients were treated with either alarm or desmopressin therapy.

RESULTS

The urinary NGF/creatinine and BDNF/creatinine ratios were significantly higher in the patient group than in the control group (P = .0003 and P = .0095, respectively). NGF and BDNF levels showed a significant positive correlation (P = .0020, r = 0.40). With respect to the degree of response, 19 patients (50%) showed complete response (CR) or partial response (PR), and 19 patients (50%) showed nonresponse (NR). The urinary NGF/creatinine and BDNF/creatinine ratios were significantly higher in the NR group than in the CR and PR groups (P = .0003 and P = .0003, respectively).

CONCLUSIONS

Urinary NGF/creatinine and BDNF/creatinine ratios were significantly higher in children with MNE than in healthy controls. Urinary NGF/creatinine can be predictive factors of a poor treatment outcome in children with MNE.

Authors+Show Affiliations

Department of Urology, Nara Medical University, Nara, Japan.Department of Urology, Nara Medical University, Nara, Japan.Department of Urology, Nara Medical University, Nara, Japan.Department of Urology, Nara Medical University, Nara, Japan.Department of Urology, Nara Medical University, Nara, Japan.Department of Urology, Nara Medical University, Nara, Japan.Department of Urology, Nara Medical University, Nara, Japan.Department of Urology, Nara Medical University, Nara, Japan.Department of Urology, Nara Medical University, Nara, Japan.Department of Urology, Nara Medical University, Nara, Japan.Department of Urology, Nara Medical University, Nara, Japan.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31432572

Citation

Morizawa, Yosuke, et al. "Urinary Nerve Growth Factor Can Predict Therapeutic Efficacy in Children With Monosymptomatic Nocturnal Enuresis." Neurourology and Urodynamics, vol. 38, no. 8, 2019, pp. 2311-2317.
Morizawa Y, Aoki K, Iemura Y, et al. Urinary nerve growth factor can predict therapeutic efficacy in children with monosymptomatic nocturnal enuresis. Neurourol Urodyn. 2019;38(8):2311-2317.
Morizawa, Y., Aoki, K., Iemura, Y., Hori, S., Gotoh, D., Fukui, S., Nakai, Y., Miyake, M., Torimoto, K., Tanaka, N., & Fujimoto, K. (2019). Urinary nerve growth factor can predict therapeutic efficacy in children with monosymptomatic nocturnal enuresis. Neurourology and Urodynamics, 38(8), 2311-2317. https://doi.org/10.1002/nau.24142
Morizawa Y, et al. Urinary Nerve Growth Factor Can Predict Therapeutic Efficacy in Children With Monosymptomatic Nocturnal Enuresis. Neurourol Urodyn. 2019;38(8):2311-2317. PubMed PMID: 31432572.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Urinary nerve growth factor can predict therapeutic efficacy in children with monosymptomatic nocturnal enuresis. AU - Morizawa,Yosuke, AU - Aoki,Katsuya, AU - Iemura,Yusuke, AU - Hori,Shunta, AU - Gotoh,Daisuke, AU - Fukui,Shinji, AU - Nakai,Yasushi, AU - Miyake,Makito, AU - Torimoto,Kazumasa, AU - Tanaka,Nobumichi, AU - Fujimoto,Kiyohide, Y1 - 2019/08/20/ PY - 2019/04/26/received PY - 2019/07/26/accepted PY - 2019/8/23/pubmed PY - 2020/5/8/medline PY - 2019/8/22/entrez KW - BDNF KW - NGF KW - biomarker KW - monosymptomatic nocturnal enuresis SP - 2311 EP - 2317 JF - Neurourology and urodynamics JO - Neurourol Urodyn VL - 38 IS - 8 N2 - AIM: To determine the urinary levels of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in children with monosymptomatic nocturnal enuresis (MNE) and evaluate whether these factors can be used as biomarkers for the treatment outcome. METHODS: NGF and BDNF levels were measured and compared in 38 children (28 boys and 10 girls) with MNE and 25 children (18 boys and 7 girls) with no urinary symptoms were assessed. The mean ages in the patient and control groups were 9 and 10 years, respectively (P = .49). The patients were treated with either alarm or desmopressin therapy. RESULTS: The urinary NGF/creatinine and BDNF/creatinine ratios were significantly higher in the patient group than in the control group (P = .0003 and P = .0095, respectively). NGF and BDNF levels showed a significant positive correlation (P = .0020, r = 0.40). With respect to the degree of response, 19 patients (50%) showed complete response (CR) or partial response (PR), and 19 patients (50%) showed nonresponse (NR). The urinary NGF/creatinine and BDNF/creatinine ratios were significantly higher in the NR group than in the CR and PR groups (P = .0003 and P = .0003, respectively). CONCLUSIONS: Urinary NGF/creatinine and BDNF/creatinine ratios were significantly higher in children with MNE than in healthy controls. Urinary NGF/creatinine can be predictive factors of a poor treatment outcome in children with MNE. SN - 1520-6777 UR - https://www.unboundmedicine.com/medline/citation/31432572/Urinary_nerve_growth_factor_can_predict_therapeutic_efficacy_in_children_with_monosymptomatic_nocturnal_enuresis_ L2 - https://doi.org/10.1002/nau.24142 DB - PRIME DP - Unbound Medicine ER -